ABSTRACT

The use of antivascular endothelial growth factors such as bevacizumab and ranibizumab has brought about a revolution in management protocols of various ophthalmic disorders. A lot has been written about these agents, still lacunae exist in our understanding due to paucity of randomized control trials with large number of patients. This brief review attempts to throw light on the clinical applications of these molecules for glaucoma.

Keywords: Bevacizumab, Glaucoma, Intraocular pressure, VEGF.

CONCEPT

The concept of a diffusable factor that affects the budding of new vessels was proposed initially in 1954, which has since been substantiated by the active research into the signal transduction pathway that leads to ocular angiogenesis.

A critically important angiogenic factor in ocular neovascularization is VEGF—vascular endothelial growth factor, an endothelial cell mitogen; which till date is the best studied and described component of this pathway. VEGF is a 46 kDa glycoprotein noted in highly vascularized tumors. Four isoforms have been identified and are instrumental in both the normal and pathologic process of angiogenesis and furthermore—as a vascular permeability factor inducing hyperpermeability, endothelial cell migration and proliferation. The critical role of VEGF in the mediation of active anterior segment intraocular neovascularization in patients with ischemic retinal disease has been demonstrated through observations of significantly increased levels of VEGF in the vitreous and aqueous humor.

Molecule

Bevacizumab is a recombinant humanized anti-VEGF immunoglobulin G1 (IgG1) approved as an antiangiogenic agent for the treatment of metastatic colorectal cancer in combination with chemotherapy. By binding to two receptor kinases [VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1)], bevacizumab is able to downregulate the mitogenic, angiogenic and permeability-enhancing effects of VEGF A. Avastin® (bevacizumab) is clear to slightly opalescent, colorless to pale brown, sterile solution with pH 6.2. It was originally designed for intravenous (IV) infusion and is supplied in 100 mg and 400 mg preservative-free, single-use vials to deliver 4 ml or 16 ml of Avastin® (25 mg/ml). The product is formulated in alpha-trehalose dihydrate, sodium phosphate (monobasic, monohydrate), sodium phosphate (dibasic, anhydrous), polysorbate and water for injection.
Bakri et al studied the pharmacokinetics of bevacizumab and found that the vitreous half-life of 1.25 mg IVB is 4.32 days in a rabbit eye. They also found small amounts of bevacizumab in the serum and in the fellow un.injected eye. Wakabayashi et al concluded in their study that IVB effectively stabilized NVI activity and controlled IOP in patients with NVI alone. But, in patients with advanced NVG and closed angles, IVB did not control IOP. It did, however, show promise as an adjunct to improve subsequent surgeries.

Recently, the effect of bevacizumab to posterior chamber behind iris (BIPC) combined with seton implantation in NVG patients has been studied and the researchers found significant reduction of iris neovascularization within 1 week after the injection and the effect persisted for 6 months. During the drainage device implantation, they noted decreased peroperative risk of anterior segment bleeding, increased surgical comfort and prevention of failure of filtration procedure by inhibition of reproliferation.

Marey et al combined IVB with retinal photocoagulation in 20 eyes with NVG, nine of which underwent subsequent scleral trabeculectomy with mitomycin C (MMC). All cases showed complete regression of iris neovessels at 2 months postinjection with recurrence of iris neovessels in four cases (20%) at 4 months and in 14 cases (70%) at 8 months follow-up. The mean IOP dropped significantly from 41.45 ± 5.89 mm Hg preoperatively to 19.3 ± 5.5 mm Hg and 17.75 ± 3.74 mm Hg at 6 and 12 months postoperatively, respectively. The success rate of scleral trabeculectomy with mitomycin C after intravitreal bevacizumab was good at 77.8%. They concluded that intravitreal bevacizumab has a role in regression of iris neovessels and IOP control in neovascular glaucoma and increases the success rate of scleral trabeculectomy with MMC; but this role had a limited time and reinjection is needed to maintain the effect.

Results for anti-VEGF agents for NVG seem promising in retarding and reversing the growth of vessels in the angle. In absence of peripheral anterior synechiae, bevacizumab has profound effects on IOP control. Patients experience less ocular discomfort soon after its use. In conjunction with Panretinal photocoagulation (PRP), the use of anti-VEGF agents holds great promise in improving the otherwise dismal long-term visual prognosis for patients with NVG.

**Is Bevacizumab Meant only for Regression of Neovascularization?**

Cornish et al postulated that in addition to bevacizumab’s antineovascular effect, it modulates wound healing, thereby allowing the trabeculectomy to potentially be more successful in this often difficult to manage subgroup. Yoshida et al demonstrated reduced vascular permeability, decreased inflammatory reaction, loss of vascular function and endothelial cell degeneration in trabecular tissues of patients undergoing trabeculectomy for NVG.

Due to anti-VEGF’s effect on wound healing, it has been studied as an adjunct in trabeculectomy surgery as well.

**Wound Modulation in Trabeculectomy**

The predictability in the outcome of trabeculectomy is hampered by variability in the wound healing response. Tenon fibroblasts are the main effector cells in the initiation and mediation of most wound healing and fibrotic scar formation.

After trabeculectomy and other forms of glaucoma filtration surgery, the conjunctival and episcleral fibrosis occurs as a result of progressive fibroblast migration, proliferation, collagen deposition and angiogenesis at the site of filtration. Histologic studies have shown that the maximum proliferation of subconjunctival fibroblasts occurs in the third to fifth postoperative day. Pharmacologic enhancement of trabeculectomy using 5-fluorouracil (5-FU) and MMC has improved rates of success significantly. However, the nonspecific mechanism of action of these agents may result in widespread cell death and thin-walled avascular blebs that are susceptible to leakage, infection and dysesthesias.

VEGF seem to drive fibrosis via angiogenesis, but also there is evidence of a more direct effect on fibroblastic activity. VEGF has been shown to be a mediator in the signal transduction cascade leading to fibroblast migration and proliferation. As a powerful inducer of angiogenesis, VEGF also promotes early migration of inflammatory cells and fibroblasts.

Studies by Bergen et al on various isoforms of VEGF show VEGF165 and VEGF121 predominantly affect blood vessel growth, whereas VEGF189 is more important in fibrosis. Selective inhibition of VEGF165 by pegaptinib (Macugen, Pfizer, an aptamer which specifically blocks VEGF165) may, therefore, be less effective to reduce ocular scar formation than nonselective VEGF inhibition by bevacizumab.

In the first report describing the use of bevacizumab to modulate wound healing in humans, Kahook et al noted a significant and lasting decrease in IOP after a bleb needling procedure after failed trabeculectomy. The utility of subconjunctival bevacizumab injections administered proximal to blebs after trabeculectomy at the earliest sign of vascularization was suggested by Kapetansky et al. Nearly two thirds of the blebs had an observable
Bevacizumab in Glaucoma: Where do We Stand?

Adverse Events associated with Bevacizumab

As the use of bevacizumab in the treatment of various ocular pathologies has emerged, the short-term safety data for intravitreal administration suggest the adverse event rate to not exceed 0.21%, with a majority of these events related to the administration of any intravitreal injection.

Higashide et al.33 in their retrospective study of 84 eyes with NVG found that 3% cases with NVG due to ocular ischemic syndrome developed central retinal artery occlusion. None of the cases had marked inflammation, lens injuries, marked vitreous hemorrhage, retinal detachment, endophthalmitis and none experienced systemic side-effects, including myocardial infarction and cerebrovascular accidents within 3 months after bevacizumab injection.

Wittström et al.34 investigated the electrophysiologic effect of intravitreal bevacizumab and concluded that it may reduce the photoreceptor function in NVG patients.

Safety data from long-term randomized controlled trials for bevacizumab is still lacking. In a randomized, prospective interventional study by Chua et al., 43 eyes of 39 patients who underwent uncomplicated primary antimetabolite augmented trabeculectomy who subsequently required postoperative subconjunctival 5-FU injection within 4 weeks of surgery were recruited; 21 eyes were randomized to subconjunctival injections of 5-FU and 22 eyes to combined 5-FU/bevacizumab. By 18 months after receiving the injections, 47.4% of the 5-FU/bevacizumab group exhibited central bleb avascularity compared with 21.1% of the 5-FU group (Fisher’s exact test, p = 0.17). Two bleb complications (1 blebitis; 1 suture abscess) were noted in the 5-FU/bevacizumab group. The authors suggested the need for a larger clinical trial to further evaluate the safety and efficacy of bevacizumab as a modulating agent in glaucoma filtration surgery.

Take Home Message

The antiangiogenic and antifibroblastic properties of the recently introduced anti-VEGF agents have led to their early adoption in treating NVG and influencing wound modulation post trabeculectomy. Prospective multicenter studies are still lacking for these pharmacotherapies for determining treatment regimens, most appropriate route of delivery, optimum dose for each agent, adverse effects and potential patient population that might be more susceptible to currently unknown side effects. In addition, the potential for anti-VEGF delivery systems used in conjunction with glaucoma drainage devices may be explored.

REFERENCES


ABOUT THE AUTHOR

Anjani Khanna
Glaucoma Services, Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India, e-mail: anjanikhanna@gmail.com